5,030 results match your criteria European Journal of Nuclear Medicine and Molecular Imaging[Journal]


[Ga]Pentixafor PET/MR imaging of chemokine receptor 4 expression in the human carotid artery.

Eur J Nucl Med Mol Imaging 2019 Apr 19. Epub 2019 Apr 19.

Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.

Purpose: Type 4 chemokine receptor (CXCR4) plays an important role in immune cell migration during the atherosclerosis progression. We aimed to evaluate [Ga]Pentixafor positron emission tomography (PET) in combination magnetic resonance imaging (MRI) for in vivo quantification of CXCR4 expression in carotid plaques.

Methods: Seventy-two patients with lymphoma were prospectively scheduled for whole body [Ga]Pentixafor PET/MRI with an additional T2-weighted carotid sequence. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00259-019-04322-7
Publisher Site
http://dx.doi.org/10.1007/s00259-019-04322-7DOI Listing
April 2019
1 Read

Endorsement of International Consensus Radiochemistry Nomenclature Guidelines.

Eur J Nucl Med Mol Imaging 2019 Apr 16. Epub 2019 Apr 16.

Department of Radiology and Medical Physics, Hospital de Sant Pau, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4243-5DOI Listing

Correction to: F-DOPA PET/CT in brain tumors: impact on multidisciplinary brain tumor board decisions.

Eur J Nucl Med Mol Imaging 2019 Apr 13. Epub 2019 Apr 13.

Department of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d'Azur (UCA), 33 Avenue de Valombrose, 06100, Nice, France.

Jérôme Barriere was inadvertently missing in the original version of this article. He has participated to the study design, protocol writing and inclusion of a significant number of patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04321-8DOI Listing

Distinct FP-CIT PET patterns of Alzheimer's disease with parkinsonism and dementia with Lewy bodies.

Eur J Nucl Med Mol Imaging 2019 Apr 12. Epub 2019 Apr 12.

Department of Neurology, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, 30722, South Korea.

Purpose: Little is known regarding the clinical relevance or neurobiology of subtle motor disturbance in Alzheimer's disease (AD). This study aims to investigate the patterns of striatal F-FP-CIT uptake in patients with AD-related cognitive impairment (ADCI) with mild parkinsonism.

Methods: We recruited 29 consecutive patients with ADCI with mild parkinsonism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04315-6DOI Listing
April 2019
1 Read
5.383 Impact Factor

Confirmation of the prognostic value of pretherapeutic tumor SUR and MTV in patients with esophageal squamous cell carcinoma.

Eur J Nucl Med Mol Imaging 2019 Apr 4. Epub 2019 Apr 4.

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin, Institute of Health, Department of Radiation Oncology, Berlin, Germany.

Purpose: The prognosis for patients with inoperable esophageal carcinoma is still poor and the reliability of individual therapy outcome prediction based on clinical parameters is not convincing. In a recent publication, we were able to show that PET can provide independent prognostic information in such a patient group and that the tumor-to-blood standard uptake ratio (SUR) can improve the prognostic value of tracer uptake values. The present investigation addresses the question of whether the distinctly improved prognostic value of SUR can be confirmed in a similar patient group that was examined and treated at a different site. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04307-6DOI Listing
April 2019
1 Read

Breaking an unhelpful circle, where innovation and regularia delay clinical practice for patient benefit.

Eur J Nucl Med Mol Imaging 2019 Apr 3. Epub 2019 Apr 3.

Department of Biomedical Sciences, Humanitas University, Rozzano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04304-9DOI Listing

Prognostic value of metabolic tumour volume on baseline F-FDG PET/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI.

Eur J Nucl Med Mol Imaging 2019 Apr 2. Epub 2019 Apr 2.

Department of Nuclear Medicine, Seoul National University, College of Medicine, Daehangro 101, Jongno-gu, Seoul, 03080, South Korea.

Purpose: The purpose of this study was to determine the prognostic value of metabolic volumetric parameters as a quantitative index on pre-treatment F-FDG PET/CT in addition to the National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) in patients with diffuse large B-cell lymphoma (DLBCL).

Methods: A total of 103 consecutive patients with DLBCL and baseline FDG PET/CT were retrospectively evaluated. Quantitative metabolic parameters, including total metabolic tumour volume (TMTV) using a standardized uptake value (SUV) of ≥2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04309-4DOI Listing
April 2019
3 Reads
5.383 Impact Factor

Clinical significance of amyloid β positivity in patients with probable cerebral amyloid angiopathy markers.

Eur J Nucl Med Mol Imaging 2019 Apr 2. Epub 2019 Apr 2.

Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea.

Purpose: We investigated the frequency and clinical significance of amyloid β (Aβ) positivity on PET in patients with cerebral amyloid angiopathy (CAA).

Methods: We recruited 65 patients who met the modified Boston criteria for probable CAA. All underwent amyloid PET, MRI, APOE genotyping and neuropsychological testing, and we obtained information on MRI markers of CAA and ischemic cerebral small-vessel disease (CSVD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04314-7DOI Listing
April 2019
2 Reads

The potential for PET-guided revascularization of coronary artery disease.

Eur J Nucl Med Mol Imaging 2019 Apr 2. Epub 2019 Apr 2.

Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, ON, K1Y 4W7, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04316-5DOI Listing
April 2019
1 Read

Exploratory radiomic features from integrated F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging are associated with contemporaneous metastases in oesophageal/gastroesophageal cancer.

Eur J Nucl Med Mol Imaging 2019 Mar 27. Epub 2019 Mar 27.

Department of Cancer Imaging, School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.

Purpose: The purpose of this study was to determine if F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging (F-FDG PET/MRI) features are associated with contemporaneous metastases in patients with oesophageal/gastroesophageal cancer.

Methods: Following IRB approval and informed consent, patients underwent a staging PET/MRI following F-FDG injection (326 ± 28 MBq) and 156 ± 23 min uptake time. First-order histogram and second-order grey level co-occurrence matrix features were computed for PET standardized uptake value (SUV) and MRI T1-W, T2-W, diffusion weighted (DWI) and apparent diffusion coefficient (ADC) images for the whole tumour volume. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04306-7DOI Listing

Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging.

Eur J Nucl Med Mol Imaging 2019 Mar 27. Epub 2019 Mar 27.

Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Clinical Geriatrics, Karolinska Institutet, Stockholm, Sweden.

Purpose: Several tracers have been designed for tracking the abnormal accumulation of tau pathology in vivo. Recently, concerns have been raised about the sources of off-target binding for these tracers; inconclusive data propose binding for some tracers to monoamine oxidase B (MAO-B).

Methods: Molecular docking and dynamics simulations were used to estimate the affinity and free energy for the binding of several tau tracers (FDDNP, THK523, THK5105, THK5317, THK5351, T807 [aka AV-1451, flortaucipir], T808, PBB3, RO-948, MK-6240, JNJ-311 and PI-2620) to MAO-B. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00259-019-04305-8
Publisher Site
http://dx.doi.org/10.1007/s00259-019-04305-8DOI Listing
March 2019
3 Reads

PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy.

Eur J Nucl Med Mol Imaging 2019 Mar 26. Epub 2019 Mar 26.

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.

Purpose: To assess the role of radiomics parameters in predicting pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in patients with locally advanced breast cancer.

Methods: Seventy-nine patients who had undergone pretreatment staging F-FDG PET/CT and treatment with NAC between January 2010 and January 2018 were included in the study. Primary lesions on PET images were delineated, and extraction of first-, second-, and higher-order imaging features was performed using LIFEx software. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04313-8DOI Listing
March 2019
1 Read

Clinical impact of [F]flutemetamol PET among memory clinic patients with an unclear diagnosis.

Eur J Nucl Med Mol Imaging 2019 Mar 26. Epub 2019 Mar 26.

Department of Neurobiology, Care Sciences and Society, Division of Clinical Geriatrics Center for Alzheimer Research, Karolinska Institutet, Neo, 7th floor, 141 83, Huddinge, Sweden.

Purpose: To investigate the impact of amyloid PET with [F]flutemetamol on diagnosis and treatment management in a cohort of patients attending a tertiary memory clinic in whom, despite extensive cognitive assessment including neuropsychological testing, structural imaging, CSF biomarker analysis and in some cases [F]FDG PET, the diagnosis remained unclear.

Methods: The study population consisted of 207 patients with a clinical diagnosis prior to [F]flutemetamol PET including mild cognitive impairment (MCI; n = 131), Alzheimer's disease (AD; n = 41), non-AD (n = 10), dementia not otherwise specified (dementia NOS; n = 20) and subjective cognitive decline (SCD; n = 5).

Results: Amyloid positivity was found in 53% of MCI, 68% of AD, 20% of non-AD, 20% of dementia NOS, and 60% of SCD patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04297-5DOI Listing
March 2019
2 Reads

Low hexokinase-2 expression-associated false-negative F-FDG PET/CT as a potential prognostic predictor in patients with multiple myeloma.

Eur J Nucl Med Mol Imaging 2019 Mar 22. Epub 2019 Mar 22.

Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, 929 Higashi-chou, Kamogawa, Chiba, 296-8602, Japan.

Purpose: False-negative F-FDG PET/CT, which is associated with low hexokinase-2 (HK2) expression in multiple myeloma (MM), is a new concept that is relevant for diagnosis and treatment response assessment. This study aimed to investigate the prognostic relevance of low HK2 expression-associated false-negative PET/CT in patients with MM.

Methods: Ninety consecutive patients, with newly diagnosed MM, receiving novel agents during induction therapy were enrolled in this retrospective study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04312-9DOI Listing

Development and validation of the PET-CT score for diagnosis of malignant pleural effusion.

Eur J Nucl Med Mol Imaging 2019 Mar 22. Epub 2019 Mar 22.

Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, 8 Gongti Nanlu, Chao-Yang District, Beijing, 100020, China.

Purpose: Although some parameters of positron emission tomography with F-fluorodeoxyglucose (F-FDG) and computed tomography (PET-CT) are somehow helpful in differentiating malignant pleural effusion (MPE) from benign effusions, no individual parameter offers sufficient evidence for its implementation in the clinical practice. The aim of this study was to establish the diagnostic accuracy of a scoring system based on PET-CT (the PET-CT score) in diagnosing MPE.

Methods: One prospective derivation cohort of patients with pleural effusions (84 malignant and 115 benign) was used to develop the PET-CT score for the differential diagnosis of malignant pleural effusion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04287-7DOI Listing
March 2019
1 Read
5.383 Impact Factor

Prospective comparison of whole-body MRI and Ga-PSMA PET/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy.

Eur J Nucl Med Mol Imaging 2019 Mar 16. Epub 2019 Mar 16.

Department of Nuclear Medicine, University Dusseldorf, Medical Faculty, 40225, Dusseldorf, Germany.

Purpose: To assess whole-body magnetic resonance imaging (wb-MRI) for detection of biochemical recurrence in comparison to Ga-prostate-specific membrane antigen positron emission tomography/computed tomography (Ga-PSMA PET/CT) in prostate cancer (Pca) patients after radical prostatectomy.

Methods: This was a prospective trial including 28 consecutive patients (mean age 65.3 ± 9. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04308-5DOI Listing

Ga-DOTANOC and F-DOPA PET/CT: a site-specific approach to the imaging of parangliomas of the head and neck  and of the abdomen.

Eur J Nucl Med Mol Imaging 2019 Mar 14. Epub 2019 Mar 14.

Nuclear Medicine, DIMES University of Bologna, S.Orsola-Malpighi Hospital, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04299-3DOI Listing

Radiotherapy boost in patients with hypoxic lesions identified by F-FMISO PET/CT in non-small-cell lung carcinoma: can we expect a better survival outcome without toxicity? [RTEP5 long-term follow-up].

Eur J Nucl Med Mol Imaging 2019 Mar 13. Epub 2019 Mar 13.

Department of Nuclear Medicine, Henri Becquerel Cancer Center and Rouen University Hospital, & QuantIF - LITIS [EA (Equipe d'Accueil) 4108 - FR CNRS 3638], Faculty of Medicine, University of Rouen, Rouen, France.

Purpose: Chemoradiotherapy is the reference curative-intent treatment for nonresectable locally advanced non-small-cell lung carcinoma (NSCLC), with unsatisfactory survival, partially due to radiation resistance in hypoxic tissues. The objective was to update survival and toxicity at 3 years following radiotherapy boost to hypoxic tumours in NSCLC patients treated with curative-intent chemoradiotherapy.

Methods: This was an open-label, nonrandomized, multicentre, phase II clinical trial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04285-9DOI Listing
March 2019
2 Reads

One-stop shopping F-FDG PET/CT in a patient with vascular type Behçet's disease.

Eur J Nucl Med Mol Imaging 2019 Mar 12. Epub 2019 Mar 12.

Department of Radiology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04293-9DOI Listing
March 2019
2 Reads

Small-voxel reconstructions significantly influence SUVs in PET imaging.

Eur J Nucl Med Mol Imaging 2019 Mar 13. Epub 2019 Mar 13.

Department of Medical Physics, Isala, Zwolle, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04301-yDOI Listing
March 2019
1 Read

Is there a difference in regional read [F]flutemetamol amyloid patterns between end-of-life subjects and those with amnestic mild cognitive impairment?

Eur J Nucl Med Mol Imaging 2019 Mar 13. Epub 2019 Mar 13.

GE Healthcare Life Sciences, Marlborough, MA, USA.

Purpose: Visual interpretation of PET [F]flutemetamol images relies on systematic review of five brain regions and is considered positive when an elevated signal is observed in at least one region. Amnestic mild cognitive impairment (aMCI) is an early clinical presentation of Alzheimer's disease (AD); hence it is of interest to determine if the pattern of visually read regional positivity between end-of-life (EoL) patients with and without dementia and aMCI patients is different.

Methods: A total of 180 EoL patients with and without dementia (mean age 81 years, range 59 to 95 years) and 232 aMCI patients (mean age 71 years, range 53 to 91 years) were scanned following intravenous administration of 185-370 MBq [F]flutemetamol. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04282-yDOI Listing
March 2019
1 Read

18F-Flurodeoxyglucose positron emission tomography with computed tomography (FDG PET/CT) findings in children with encephalitis and comparison to conventional imaging.

Eur J Nucl Med Mol Imaging 2019 Mar 12. Epub 2019 Mar 12.

Division of Nuclear Medicine, Department of Medical Imaging, Centre Hospitalier Universitaire Sainte-Justine, 3175 Chemin de la Côte-Sainte-Catherine, Montréal, Québec, H3T 1C5, Canada.

Purpose: FDG PET/CT is emerging as a new tool for the evaluation of acute encephalitis (AE). However, to date, there are no exclusively pediatric studies on the use of FDG PET for suspected AE. The objective of this study was to compare qualitative and quantitative brain PET to conventional brain imaging in a cohort of children, and to identify patterns of metabolic abnormalities characteristic of AE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04302-xDOI Listing
March 2019
2 Reads

TSH suppression aggravates arterial inflammation - an F-FDG PET study in thyroid carcinoma patients.

Eur J Nucl Med Mol Imaging 2019 Mar 11. Epub 2019 Mar 11.

Department of Radiology and Nuclear Medicine, Maastricht University Medical Centre (MUMC+), P. Debyelaan 25, 6229 HX, Maastricht, The Netherlands.

Purpose: We aimed to investigate the influence of both hypothyroidism and thyroid-stimulating hormone (TSH) suppression on vascular inflammation, as assessed with F-fluorodeoxyglucose (F-FDG) positron emission tomography (PET)/computed tomography (CT).

Methods: Ten thyroid carcinoma patients underwent an F-FDG PET/CT during post-thyroidectomy hypothyroidism and during thyrotropin (TSH) suppression after I (radioiodine) ablation therapy. We analysed the F-FDG uptake in the carotids, aortic arch, ascending, descending, and abdominal aorta to investigate the effects of thyroid hormone status on arterial inflammation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04292-wDOI Listing
March 2019
1 Read

Digital PET/CT: a new intriguing chance for clinical nuclear medicine and personalized molecular imaging.

Eur J Nucl Med Mol Imaging 2019 Mar 11. Epub 2019 Mar 11.

Nuclear Medicine, Policlinico Tor Vergata, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04300-zDOI Listing

F-FPPRGD PET/CT in patients with metastatic renal cell cancer.

Eur J Nucl Med Mol Imaging 2019 Mar 8. Epub 2019 Mar 8.

Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, 300 Pasteur Drive, Stanford, CA, 94305-5281, USA.

Purpose: The usefulness of positron emission tomography/computed tomography (PET/CT) using (F)-2-fluoropropionyl-labeled PEGylated dimeric arginine-glycine-aspartic acid peptide [PEG3-E{c(RGDyk)}2] (F-FPPRGD) in patients with metastatic renal cell cancer (mRCC) has not been evaluated; therefore, we were prompted to conduct this pilot study.

Methods: Seven patients with mRCC were enrolled in this prospective study. F-FPPRGD and 2-deoxy-2-(F)fluoro-D-glucose (F-FDG) PET/CT images were evaluated in a per-lesion analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04295-7DOI Listing

F-FDG uptake of brown fat and cancer: casualty or causality?

Eur J Nucl Med Mol Imaging 2019 Mar 8. Epub 2019 Mar 8.

Department of Nuclear Medicine, Humanitas Research Hospital, Rozzano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04303-wDOI Listing

Clinical utility of Ga-DOTATOC positron emission tomography/computed tomography for recurrent renal cell carcinoma.

Eur J Nucl Med Mol Imaging 2019 Mar 7. Epub 2019 Mar 7.

Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, 54 Shogoinkawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.

Purpose: Positron emission tomography (PET)/computed tomography (CT) with Ga-labelled 1,4,7,10-tetraazacyclododecane-N,N',N″,N″'-tetraacetic acid-D-Phe-Tyr-octreotide (DOTATOC) has been accepted as a diagnostic imaging tool especially for patients with neuroendocrine tumours. However, its clinical usefulness for restaging of renal cell carcinoma (RCC) has not been fully investigated. This retrospective study was performed to elucidate the clinical value of PET/CT using Ga-DOTATOC in patients with known or suspected recurrent RCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04298-4DOI Listing

Dosimetry-based high-activity therapy with I-metaiodobenzylguanidine (I-mIBG) and topotecan for the treatment of high-risk refractory neuroblastoma.

Eur J Nucl Med Mol Imaging 2019 Mar 5. Epub 2019 Mar 5.

Department of Pediatric Oncology and Hematology, Cruces University Hospital, Plaza de Cruces s/n, 48903, Baracaldo, Vizcaya, Spain.

Purpose: Patients with high-risk neuroblastoma have an increased risk of recurrence and relapse of disease and a very poor prognosis. I-metaiodobenzylguanidine (I-mIBG) in combination with topotecan as a radiosensitizer can be an effective and relatively well-tolerated agent for the treatment of refractory neuroblastoma. The aim of this retrospective study was to evaluate response and outcome of combined therapy with I-mIBG and topotecan. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04291-xDOI Listing
March 2019
2 Reads

In response to: The validity of F-GE180 as a TSPO imaging agent.

Eur J Nucl Med Mol Imaging 2019 Mar 2. Epub 2019 Mar 2.

Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04294-8DOI Listing

Comment on: Relationship between the expression of PD-1/PD-L1 and F-FDG uptake in bladder cancer.

Eur J Nucl Med Mol Imaging 2019 Mar 1. Epub 2019 Mar 1.

Department of Urology, Hôpital Foch, Université Versailles-Saint-Quentin-en-Yvelines, Université Paris-Saclay, Suresnes, France.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00259-019-04296-6
Publisher Site
http://dx.doi.org/10.1007/s00259-019-04296-6DOI Listing
March 2019
5 Reads

Baseline PET features to predict prognosis in primary mediastinal B cell lymphoma: a comparative analysis of different methods for measuring baseline metabolic tumour volume.

Eur J Nucl Med Mol Imaging 2019 Feb 26. Epub 2019 Feb 26.

Institute of Oncology Research, Bellinzona, Switzerland.

Purpose: This study assessed the performance of four different methods for the estimation of metabolic tumour volume (MTV) in primary mediastinal B cell lymphoma (PMBCL).

Method: MTV was estimated using either a region growing automatic software program (RG) or a fixed threshold (FT) segmentation algorithm with the three most common cut-offs proposed in the literature (i.e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04286-8DOI Listing
February 2019
1 Read

The impact of revascularization on myocardial blood flow as assessed by positron emission tomography.

Eur J Nucl Med Mol Imaging 2019 Feb 26. Epub 2019 Feb 26.

John Ochsner Heart and Vascular Institute, Department of Cardiovascular Diseases, 1514 Jefferson Highway, New Orleans, LA, 70121-2483, USA.

Purpose: Revascularization aims to improve myocardial perfusion. However, changes in regional artery-specific quantitative perfusion after revascularization have not been systematically investigated. It is unclear whether artery-specific thresholds for coronary flow capacity (CFC) and/or relative perfusion predict improved stress perfusion after revascularization. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04278-8DOI Listing
February 2019
1 Read

Is the effect of hyperglycemia on liver F-FDG standardized uptake value really clinically significant?

Eur J Nucl Med Mol Imaging 2019 Feb 26. Epub 2019 Feb 26.

Medical Imaging Research Laboratory, Federal University of Health Sciences of Porto Alegre, Av. Independência, 75, Porto Alegre, Rio Grande do Sul, 90020-160, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04288-6DOI Listing
February 2019
1 Read
5.383 Impact Factor

Perioperative PET/CT lymphoscintigraphy and fluorescent real-time imaging for sentinel lymph node mapping in early staged colon cancer.

Eur J Nucl Med Mol Imaging 2019 Feb 23. Epub 2019 Feb 23.

Department of Operation Rooms and MITeC Technology Center, Radboud University Medical Centre, Nijmegen, The Netherlands.

Purpose: Using current optical imaging techniques and gamma imaging modalities, perioperative sentinel lymph node (SLN) identification in colon cancer can be difficult when the SLN is located near the primary tumour or beneath a thick layer of (fat) tissue. Sentinel lymph node mapping using PET/CT lymphoscintigraphy combined with real-time visualization of the SLN using near-infrared imaging has shown promising results in several types of cancer and may facilitate the successful identification of the number and location of the SLN in early colon cancer.

Methods: Clinical feasibility of PET/CT lymphoscintigraphy using preoperative endoscopically injected [Zr]Zr-Nanocoll and intraoperative injection of the near-infrared (NIR) tracer Indocyanine Green (ICG) was evaluated in ten early colon cancer patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04284-wDOI Listing
February 2019

Detection of cardiac amyloidosis with F-Florbetaben-PET/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy.

Eur J Nucl Med Mol Imaging 2019 Feb 23. Epub 2019 Feb 23.

Department of Nuclear Medicine, University Hospital Würzburg, Oberdürrbacher Str. 6, 97078, Würzburg, Germany.

Purpose: Cardiac amyloidosis (CA) is a rare cause of heart failure with frequently delayed diagnosis, because specific early signs or symptoms are missing. Recently, direct amyloid imaging using positron emission tomography/computed tomography (PET/CT) has emerged. The aim of this study was to examine the performance of F-florbetaben-PET/CT in detection of CA, and compare it to echocardiography (echo), cardiac MRI (CMR) and scintigraphy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04290-yDOI Listing
February 2019
1 Read

Functional imaging of concomitant lingual thyroid and parathyroid adenoma.

Eur J Nucl Med Mol Imaging 2019 May 20;46(5):1201-1202. Epub 2019 Feb 20.

CHU Bordeaux, Hôpital Haut-Lévêque, Service d'Endocrinologie, Diabétologie et Nutrition, 1 avenue Magellan, 33600, Pessac, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04283-xDOI Listing

Clinical value of FDG-PET/CT in bacteremia of unknown origin with catalase-negative gram-positive cocci or Staphylococcus aureus.

Eur J Nucl Med Mol Imaging 2019 Feb 20. Epub 2019 Feb 20.

Department of Nuclear Medicine, Odense University Hospital, Sdr. Boulevard 29, Indgang 44, 46, 5000, Odense C, Denmark.

Introduction: Bacteremia is associated with high mortality, especially when the site of infection is unknown. While conventional imaging usually focus on specific body parts, FDG-PET/CT visualizes hypermetabolic foci throughout the body.

Purpose: To investigate the ability of FDG/PET-CT to detect the site of infection and its clinical impact in bacteremia of unknown origin with catalase-negative Gram-positive cocci (excluding pneumococci and enterococci) or Staphylococcus aureus (BUOCSA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04289-5DOI Listing
February 2019

F-FDG PET/CT in multiple myeloma: critical insights and future directions.

Eur J Nucl Med Mol Imaging 2019 May 15;46(5):1048-1050. Epub 2019 Feb 15.

CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04279-7DOI Listing
May 2019
2 Reads

Correction to: Digital vs. analog PET/CT: intra-subject comparison of the SUVmax in target lesions and reference regions.

Eur J Nucl Med Mol Imaging 2019 May;46(5):1204

Nuclear Medicine Department, Hospital Sant Pau, Autonomous University of Barcelona, Sant Antoni M. Claret, 167, 08025, Barcelona, Spain.

The article Digital vs. analog PET/CT: intra-subject comparison of the SUVmax in target lesions and reference regions, written by Francisco Fuentes-Ocampo, Diego Alfonso López-Mora, Albert Flotats, Gabriela Paillahueque. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04280-0DOI Listing
May 2019
1 Read

Correction to: Consensus document for the diagnosis of prosthetic joint infections: a joint paper by the EANM, EBJIS, and ESR (with ESCMID endorsement).

Eur J Nucl Med Mol Imaging 2019 May;46(5):1203

Department of Orthopaedic Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

The authors regret to inform the readers that one of the author's name in the original publication of this article was spelled incorrectly as Victor Casar-Pullicino. The correct spelling is Victor N. Cassar-Pullicino and is now presented correctly in this article. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04281-zDOI Listing

Chemoradiotherapy for locally advanced cervix cancer without aortic lymph node involvement: can we consider metabolic parameters of pretherapeutic FDG-PET/CT for treatment tailoring?

Eur J Nucl Med Mol Imaging 2019 Feb 7. Epub 2019 Feb 7.

Department of Surgical Oncology, IUCT-Oncopole, 1 avenue Irène Joliot-Curie, 31059, Toulouse Cedex 9, France.

Purpose: Aim of the study was to assess impact of pretherapeutic FDG-PET/CT metabolic parameters on response to chemoradiotherapy (CRT) and survival in locally advanced cervical cancer (LACC) patients without paraaortic lymph node involvement.

Methods: LACC patients treated with CRT without macrometastatic involvement after paraaortic surgical staging were included. All patients had received at least 45 Gy radiotherapy and five cycles of platinum-based chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4219-5DOI Listing
February 2019
2 Reads

Preliminary results of the Phase 1 Lip-Re I clinical trial: biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with Re-SSS Lipiodol radioembolization.

Eur J Nucl Med Mol Imaging 2019 Feb 4. Epub 2019 Feb 4.

Department of Nuclear Medicine, Cancer Institute Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, CS 44229, 35042, Rennes, cedex, France.

Purpose: This study sought to provide preliminary results on the biodistribution and dosimetry following intra-arterial liver injection of Re-SSS Lipiodol on hepatocellular carcinoma patients included in the Phase I Lip-Re 1 study.

Methods: Results of the first six patients included are reported. Analysis of the Re-SSS Lipiodol biodistribution was based on planar scintigraphic and tomoscintigraphic (SPECT) studies performed at 1, 6, 24, 48, and 72 h post-administration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04277-9DOI Listing
February 2019
4 Reads

Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: analysis of the ESPATUE randomized phase 3 trial.

Eur J Nucl Med Mol Imaging 2019 Feb 1. Epub 2019 Feb 1.

Department of Radiation Oncology, West German Cancer Center, University of Duisburg-Essen Medical School, Hufelandstr. 55, 45122, Essen, Germany.

Purpose: According to the ACRIN 6668/RTOG 0235 trial, pretreatment metabolic tumour volume (MTV) as detected by F-fluorodeoxyglucose PET/CT is a prognostic factor in patients with stage III non-small-cell lung cancer (NSCLC) after definitive radiochemotherapy (RCT). To validate the prognostic value of MTV in patients with stage III NSCLC after RCT, we analysed mature survival data from the German phase III trial ESPATUE.

Methods: This analysis included patients who were staged by PET/CT and who were enrolled in the ESPATUE trial, a randomized study comparing definitive RCT (arm A) with surgery (arm B) after induction chemotherapy and RCT in patients with resectable stage IIIA/IIIB NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-4270-xDOI Listing
February 2019
3 Reads

Ga-PSMA PET/CT for monitoring response to Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer.

Eur J Nucl Med Mol Imaging 2019 May 29;46(5):1054-1062. Epub 2019 Jan 29.

Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.

Purpose: To evaluate the use of Ga-PSMA PET/CT for monitoring response to Lu-617 PSMA radioligand therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC).

Methods: Patients from the University Hospital Bonn and the University Hospital Aachen were retrospectively reviewed for this study. We included 48 patients with mCRPC who were treated with Lu-PSMA-617 and whose records included Ga-PSMA PET/CT imaging before the first and after the third or fourth treatment cycle. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-4258-6DOI Listing

Imaging of tau deposits in adults with Niemann-Pick type C disease: a case-control study.

Eur J Nucl Med Mol Imaging 2019 May 28;46(5):1132-1138. Epub 2019 Jan 28.

The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, VIC, Australia.

Purpose: Niemann-Pick type C (NPC) is a cholesterol storage disease characterized by disruption in the endosomal-lysosomal transport system that leads to the accumulation of cholesterol and glycolipids in lysosomes. Developmental cognitive delay and progressive motor and cognitive impairment are characteristic of the disease. Tau accumulation has been reported in some NPC patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-4273-7DOI Listing
May 2019
3 Reads

Economic sanctions are against basic human rights on health.

Eur J Nucl Med Mol Imaging 2019 May 28;46(5):1046-1047. Epub 2019 Jan 28.

Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-4269-3DOI Listing

Pretreatment F-FDG PET/CT combined with quantification of clonal circulating plasma cells as a potential risk model in patients with newly diagnosed multiple myeloma.

Eur J Nucl Med Mol Imaging 2019 Jan 28. Epub 2019 Jan 28.

Division of Haematology/Oncology, Department of Internal Medicine, Kameda Medical Centre, 929 Higashi-chou, Kamogawa, 296-8602, Japan.

Purpose: Both F-FDG PET/CT and clonal circulating plasma cell (CPC) quantification are emerging tools for multiple myeloma (MM) prognostication that have been validated in recent studies. This study investigated the value of PET/CT coupled with CPC quantification for MM prognostication that may contribute to future risk-adapted treatment.

Methods: We retrospectively analysed the prognostic relevance of a combination of pretreatment PET/CT findings and CPC levels in 163 consecutive patients with newly diagnosed, symptomatic MM receiving novel agents during induction therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-4275-5DOI Listing
January 2019

The mean striatal F-DOPA uptake is not a reliable cut-off threshold for biological tumour volume definition of glioma.

Eur J Nucl Med Mol Imaging 2019 May 26;46(5):1051-1053. Epub 2019 Jan 26.

Nuclear Medicine, Sant'Andrea Hospital, Department of Surgical and Medical Sciences and Translational Medicine, Faculty of Medicine and Psychology, Sapienza University of Rome, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-4276-4DOI Listing